A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test
Portfolio Pulse from Vandana Singh
Vanda Pharmaceuticals announced positive Phase 3 study results for tradipitant in motion sickness, showing its effectiveness in preventing vomiting. The study was conducted on boats in the coastal waters of the U.S. with 365 participants.
May 25, 2023 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals' tradipitant demonstrated effectiveness in preventing vomiting in a Phase 3 motion sickness study, potentially leading to a new treatment option.
The positive Phase 3 study results for tradipitant indicate its potential as a new treatment for motion sickness, which could lead to increased demand and revenue for Vanda Pharmaceuticals. This news is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100